Tafasitamab (CD19 monoclonal antibody) plus lenalidomide (tafa + len) was approved in the 2L setting for ASCT-ineligible patients with R/R DLBCL in 2021 based on the phase 2, single-arm registration trial, L-MIND (NCT02399085).19 This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.